相似文献
1
2
Advances in Immunotherapy for Glioblastoma Multiforme.
J Immunol Res. 2017;2017:3597613. doi: 10.1155/2017/3597613. Epub 2017 Feb 19.
3
Current Advances in Immunotherapy for Glioblastoma.
Curr Oncol Rep. 2021 Jan 26;23(2):21. doi: 10.1007/s11912-020-01007-5.
4
How We Treat Recurrent Glioblastoma Today and Current Evidence.
Curr Oncol Rep. 2019 Oct 12;21(10):94. doi: 10.1007/s11912-019-0834-y.
5
Dendritic cell vaccines to combat glioblastoma.
Expert Rev Neurother. 2010 Apr;10(4):483-6. doi: 10.1586/ern.10.26.
6
Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma.
World Neurosurg. 2012 May-Jun;77(5-6):633-5. doi: 10.1016/j.wneu.2011.10.012. Epub 2011 Nov 1.
7
Agenus cancer vaccine extends survival of GBM patients.
Hum Vaccin Immunother. 2014;10(2):252-3.
8
Immunotherapy in human glioblastoma.
Rev Neurol (Paris). 2011 Oct;167(10):668-72. doi: 10.1016/j.neurol.2011.07.002. Epub 2011 Aug 31.
9
Dendritic cell immunotherapy for glioblastoma.
Expert Rev Anticancer Ther. 2014 Jul;14(7):761-3. doi: 10.1586/14737140.2014.921571. Epub 2014 May 21.
10
Vaccine-based immunotherapy for glioblastoma.
CNS Oncol. 2013 Jul;2(4):331-49. doi: 10.2217/cns.13.29.
引用本文的文献
1
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.
Leukemia. 2022 Jan;36(1):138-154. doi: 10.1038/s41375-021-01301-6. Epub 2021 Jul 21.
本文引用的文献
1
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma.
Oncoimmunology. 2019 Jan 25;8(4):e1561106. doi: 10.1080/2162402X.2018.1561106. eCollection 2019.
2
Current State of Immunotherapy for Treatment of Glioblastoma.
Curr Treat Options Oncol. 2019 Feb 21;20(3):24. doi: 10.1007/s11864-019-0619-4.
3
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.
4
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
Nature. 2019 Jan;565(7738):234-239. doi: 10.1038/s41586-018-0792-9. Epub 2018 Dec 19.
5
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19.
6
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Neurology. 2018 Oct 2;91(14):e1355-e1359. doi: 10.1212/WNL.0000000000006283. Epub 2018 Aug 31.
7
Retrospective study of nivolumab for patients with recurrent high grade gliomas.
J Neurooncol. 2018 Sep;139(3):625-631. doi: 10.1007/s11060-018-2907-4. Epub 2018 May 19.
8
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Neuro Oncol. 2018 Apr 9;20(5):674-686. doi: 10.1093/neuonc/nox208.
9
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.
10
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026.
Zotero 插件